Adaptive 3-D ICBT Treatment Plans for cervical cancer: Target Volume vs. High Central Dose Profiles
PO-1337
Abstract
Adaptive 3-D ICBT Treatment Plans for cervical cancer: Target Volume vs. High Central Dose Profiles
Authors: Robert Kim1, Scott Strickler1, Samuel Marcrom2, Xingen Wu1
1University of Alabama at Birmingham, Radiation Oncology, Birmingham, USA; 2University of Alabama at Birmingham, Radiation Oncology, Birmingham , USA
Show Affiliations
Hide Affiliations
Purpose or Objective
Intracavitary brachytherapy (ICBT) not only provides
conformal dose delivery, but also delivers a high central dose (HCD) to the
target which cannot be reproduced by IMRT or SBRT. The ABS and SGO do not
recommend conformal external beam boost due to inferior local control and
survival. The ideal HCD profile for tumor control is a matter of debate. It is
well known that various treatment plans with different image-guided (IG) target
definitions can equally conform to HR-CTV and limit dose to organs at risk
(OARs) for medium-sized ICBT targets. However, HCD profiles in various
treatment plans (TP) have not been compared in the past. Target definition of
HS-CTV is the most critical for IG-ICBT. The purpose of this study is to
compare HCD profiles between conventional Point A and IG-ICBT plans with
different target definitions.
Material and Methods
Five ICBT TP with different target definition were used to
compare HCD profiles. Each TP was run on three tumor sizes – small, medium, and
large. A patient with FIGO stage IB2 cervical cancer was selected for the
medium-sized HR-CTV. A large target was created by adding a 1.0 cm symmetric
expansion and a small target by subtracting 0.5 cm symmetrically. The three Point A
based plans were evaluated: standard
Point A, Point A with inverse optimization (Point A-IO), and Point A with dose
shaping (Point A-DS). Two inverse optimization plans were evaluated: inverse plan with entire tandem length (IP-ETL)
and inverse plan with modified tandem length to fit HR-CTV (IP-MTL). Priority
for each treatment plan was HR-CTV coverage by prescribed dose (800 cGy).
Secondary priority was organ at risk constraints (rectum D2cc < 470 cGy,
bladder D2cc < 650 cGy). Target coverage, V100%, V150%, V200%, V250%, and
OAR doses were compared for each plan.
Results
The table shows target coverage (%), HCD (V150%, V200%, V250%)
and OAR doses for the five treatment plans for three target sizes. All five
treatment plans were able to achieve adequate target coverage (98-100%) and OAR
constraints for all three target sizes except the Point A plan for large
target. Point A based plans had larger V100%, V150%, V200%, and V250% than the
inverse plans, particularly for larger targets. IP-MTL plans had the smallest
HCD volumes. However, volume of HCD (V150%, V200%, V250%) relative to volume of
prescribed dose (V100%) was similar between all treatment plans and target
sizes: 46-55% for V150%, 26-35% for V200% and 17-24% for V250%.
Conclusion
Adequate target coverage and OAR constraints can be achieved
with both Point A based planning and inverse planning. Conventional Point A
based plans have larger V100% and HCD volumes compared to more modern inverse
planning. However, volume of HCD relative to volume of prescribed dose is
similar in both Point A based and inverse plans. Therefore, selecting a target
definition for ICBT is a personal choice. There is no data available which is
the best Plan for high local control with low morbidities.